Bhusari, Priya <br/><br/>
Development of Lu-177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients.  [electronic resource] 

 -  International journal of cancer  02 2017 
 - 938-947 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1097-0215 
<br/><br/><label>Standard No.: </label>10.1002/ijc.30500  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antineoplastic Agents, Hormonal--therapeutic use<br/>Breast Neoplasms--chemistry<br/>Combined Modality Therapy<br/>Feasibility Studies<br/>Female<br/>Genes, erbB-2<br/>Heterocyclic Compounds, 1-Ring--analysis<br/>Humans<br/>Immunoconjugates--administration & dosage<br/>Lutetium--administration & dosage<br/>Mastectomy<br/>Middle Aged<br/>Molecular Targeted Therapy<br/>Neoplasm Metastasis<br/>Neoplasm Proteins--antagonists & inhibitors<br/>Pilot Projects<br/>Radioimmunotherapy<br/>Radioisotopes--administration & dosage<br/>Receptor, ErbB-2--antagonists & inhibitors<br/>Single Photon Emission Computed Tomography Computed Tomography<br/>Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization<br/>Tamoxifen--therapeutic use<br/>Tissue Distribution<br/>Trastuzumab--administration & dosage